⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1669260 | 1.00 | — | — | |
| SCHEMBL19813207 | 0.88 | KDM4E (0.45) | — | |
| SCHEMBL515191 | 0.82 | KDM4E (0.52) | — | |
| SCHEMBL1146625 | 0.82 | KDM4E (0.52) | — | |
| SCHEMBL14177128 | 0.82 | — | — | |
| SCHEMBL23169663 | 0.82 | — | — | |
| SCHEMBL12409488 | 0.82 | KDM4E (0.52) | — | |
| SCHEMBL14169375 | 0.81 | — | — | |
| SCHEMBL19538682 | 0.80 | — | — | |
| SCHEMBL12341600 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-121873017-A | Preparation method of (S) - (2-oxo-tetrahydrofuran-3-yl) -carbamate | 山东省农药科学研究院 | 2026-04-17 | — | — | CN | disclosed |
| CN-121873017-A | Preparation method of (S) - (2-oxo-tetrahydrofuran-3-yl) -carbamate | 山东省农药科学研究院 | 2026-04-17 | — | — | CN | disclosed |
| EP-3458584-B1 | FUSION PROTEINS COMPRISING AN ALDOLASE ENZYME JOINED TO A MALTOSE BINDING PROTEIN | CONSEJO SUPERIOR INVESTIGACION (ES) | 2021-07-07 | — | — | EP | disclosed |
| US-10683493-B2 | Fusion proteins comprising an aldolase enzyme joined to a maltose binding protein | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (ES) | 2020-06-16 | — | — | US | disclosed |
| US-20190194638-A1 | FUSION PROTEINS COMPRISING AN ALDOLASE ENZYME JOINED TO A MALTOSE BINDING PROTEIN | TECHNICAL UNIVERSITY OF DARMSTADT (DE) | 2019-06-27 | — | — | US | disclosed |
| EP-3458584-A1 | FUSION PROTEINS COMPRISING AN ALDOLASE ENZYME JOINED TO A MALTOSE BINDING PROTEIN | Consejo Superior De Investigaciones Científicas (ES) | 2019-03-27 | — | — | EP | disclosed |
| WO-2017198717-A1 | FUSION PROTEINS COMPRISING AN ALDOLASE ENZYME JOINED TO A MALTOSE BINDING PROTEIN | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (ES) | 2017-11-23 | — | — | WO | disclosed |
| US-7728005-B2 | Ether derivative | AJINOMOTO CO., INC. (JP) | 2010-06-01 | — | — | US | disclosed |
| US-7329685-B2 | 1-Phenyl-2-oxo-3-sulfonylamino-pyrrolidine derivatives and related compounds as factor Xa inhibitors for the treatment of acute vascular diseases | GLAXO GROUP LIMITED (GB) | 2008-02-12 | — | — | US | disclosed |
| US-20070203206-A1 | 2-Pyrrolidone Derivatives And Use Thereof As Factor Xa Inhibitors | GLAXO GROUP LIMITED (GB) | 2007-08-30 | — | — | US | disclosed |
| US-20060270693-A1 | Ether derivative | AJINOMOTO CO., INC. (JP) | 2006-11-30 | — | — | US | disclosed |
| EP-1635817-B1 | 1-PHENYL-2-OXO-3-SULFONYLAMINO-PYRROLIDINE DERIVATIVES AND RELATED COMPOUNDS AS FACTOR XA INHIBITORS FOR THE TREATMENT OF ACUTE VASCULAR DISEASES | GLAXO GROUP LTD (GB) | 2006-11-22 | — | — | EP | disclosed |
| EP-1679296-A1 | ETHER DERIVATIVE | Ajinomoto Co., Inc. (JP) | 2006-07-12 | — | — | EP | disclosed |
| US-20060148879-A1 | 1-Phenyl-2-oxo-3-sulfonylamino-pyrrolidine derivatives and related compounds as factor xa inhibitors for the treatment of acute vascular diseases | GLAXO GROUP LIMITED (GB) | 2006-07-06 | — | — | US | disclosed |
| EP-1635817-A1 | 1-PHENYL-2-OXO-3-SULFONYLAMINO-PYRROLIDINE DERIVATIVES AND RELATED COMPOUNDS AS FACTOR XA INHIBITORS FOR THE TREATMENT OF ACUTE VASCULAR DISEASES | GLAXO GROUP LIMITED (GB) | 2006-03-22 | — | — | EP | disclosed |
| EP-1633347-A1 | 2-PYRROLIDONE DERIVATIVES AND USE THEREOF AS FACTOR XA INHIBITORS | GLAXO GROUP LIMITED (GB) | 2006-03-15 | — | — | EP | disclosed |
| WO-2004110435-A1 | 1-PHENYL-2-OXO-3-SULFONYLAMINO-PYRROLIDINE DERIVATIVES AND RELATED COMPOUNDS AS FACTOR XA INHIBITORS FOR THE TREATMENT OF ACUTE VASCULAR DISEASES | GLAXO GROUP LIMITED (GB) | 2004-12-23 | — | — | WO | disclosed |
| WO-2004110434-A1 | 2-PYRROLIDONE DERIVATIVES AND USE THEREOF AS FACTOR XA INHIBITORS | GLAXO GROUP LIMITED (GB) | 2004-12-23 | — | — | WO | disclosed |